There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Autolus Therapeutics (AUTL – Research Report), Amphastar Pharmaceuticals (AMPH – Research Report) and Inari Medical (NARI – Research Report) with bullish sentiments.
Autolus Therapeutics (AUTL)
Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics today and set a price target of $7.00. The company’s shares closed last Tuesday at $4.55, close to its 52-week high of $4.83.
According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.75, implying an 83.1% upside from current levels. In a report issued on November 27, Wells Fargo also maintained a Buy rating on the stock with a $6.00 price target.
See the top stocks recommended by analysts >>
Amphastar Pharmaceuticals (AMPH)
In a report issued on November 24, Nico Chen from DBS maintained a Buy rating on Amphastar Pharmaceuticals, with a price target of $55.00. The company’s shares closed last Tuesday at $54.41.
According to TipRanks.com, Chen is a 2-star analyst with an average return of
Amphastar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $59.00.
Inari Medical (NARI)
BTIG analyst Marie Thibault reiterated a Buy rating on Inari Medical today and set a price target of $93.00. The company’s shares closed last Tuesday at $58.26.
According to TipRanks.com, Thibault has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Inari Medical is a Strong Buy with an average price target of $77.71, which is a 34.0% upside from current levels. In a report issued on November 26, Wells Fargo also maintained a Buy rating on the stock with a $100.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AUTL:
- Autolus Therapeutics submits BLA to U.S. FDA for obecabtagene autoleucel
- Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
- Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
- Autolus Therapeutics initiated with a Buy at Deutsche Bank
- Biotech Alert: Searches spiking for these stocks today
